Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) – Pipeline Review, H2 2016’, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)

The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects

The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Abeome Corporation

Alnylam Pharmaceuticals, Inc.

AlphaMab Co., Ltd

AstraZeneca Plc

Aurigene Discovery Technologies Limited

Avacta Group Plc

BeiGene, Ltd.

Bristol-Myers Squibb Company

CBT Pharmaceuticals Inc

CytomX Therapeutics, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Genosco

ImmunoCellular Therapeutics, Ltd.

Immunocore Limited

IO Biotech ApS

Kadmon Corporation, LLC

Kymab Limited

MedImmune, LLC

Merck KGaA

Merus NV

Novartis AG

PsiOxus Therapeutics Limited

Regeneron Pharmaceuticals Inc

Shanghai Henlius Biotech Co., Ltd.

Sorrento Therapeutics, Inc.

Sutro Biopharma, Inc.

Theravectys SA

Tikcro Technologies, Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Overview 9

Therapeutics Development 10

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Stage of Development 10

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Therapy Area 11

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Indication 12

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Companies 17

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Universities/Institutes 30

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Therapeutics Assessment 32

Assessment by Monotherapy/Combination Products 32

Assessment by Mechanism of Action 33

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Companies Involved in Therapeutics Development 38

Abeome Corporation 38

Alnylam Pharmaceuticals, Inc. 39

AlphaMab Co., Ltd 40

AstraZeneca Plc 41

Aurigene Discovery Technologies Limited 42

Avacta Group Plc 43

BeiGene, Ltd. 44

Bristol-Myers Squibb Company 45

CBT Pharmaceuticals Inc 46

CytomX Therapeutics, Inc. 47

Eli Lilly and Company 48

F. Hoffmann-La Roche Ltd. 49

Genosco 51

ImmunoCellular Therapeutics, Ltd. 52

Immunocore Limited 53

IO Biotech ApS 54

Kadmon Corporation, LLC 55

Kymab Limited 56

MedImmune, LLC 57

Merck KGaA 59

Merus NV 60

Novartis AG 61

PsiOxus Therapeutics Limited 62

Regeneron Pharmaceuticals Inc 63

Shanghai Henlius Biotech Co., Ltd. 64

Sorrento Therapeutics, Inc. 65

Sutro Biopharma, Inc. 66

Theravectys SA 67

Tikcro Technologies, Ltd. 68

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drug Profiles 69

ALN-PDL - Drug Profile 69

Antibody to Inhibit PD-L1 for Oncology - Drug Profile 70

Antisense Oligonucleotide to Inhibit PD-L1 for Oncology - Drug Profile 71

atezolizumab - Drug Profile 72

avelumab - Drug Profile 86

AZD-1775 + durvalumab - Drug Profile 92

Biologic to Inhibit PD-L1 for Immunology - Drug Profile 93

BMS-936559 - Drug Profile 94

CA-170 - Drug Profile 96

CA-327 - Drug Profile 98

CBA-0710 - Drug Profile 99

CBT-502 - Drug Profile 100

Cellular Immunotherapy to Inhibit PD-L1 for Oncology - Drug Profile 101

CX-072 - Drug Profile 102

dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 103

durvalumab - Drug Profile 104

durvalumab + gefitinib - Drug Profile 115

durvalumab + IMCgp-100 + tremelimumab - Drug Profile 116

durvalumab + MEDI-0562 - Drug Profile 117

durvalumab + MEDI-0680 - Drug Profile 118

durvalumab + monalizumab - Drug Profile 119

durvalumab + oleclumab - Drug Profile 120

durvalumab + selumetinib sulfate - Drug Profile 121

durvalumab + tremelimumab - Drug Profile 122

FAZ-053 - Drug Profile 126

GNS-1480 - Drug Profile 127

HLX-10 - Drug Profile 128

HLX-20 - Drug Profile 129

HTI-1316 - Drug Profile 130

IO-103 - Drug Profile 131

KD-033 - Drug Profile 132

KN-035 - Drug Profile 133

KY-1003 - Drug Profile 134

LY-3300054 - Drug Profile 135

MCLA-145 - Drug Profile 136

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 137

Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 138

Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 139

Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 140

Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 141

Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile 142

Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 143

Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 144

Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 145

Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 146

Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile 147

Monoclonal Antibody to Inhibit PDL1 for Oncology - Drug Profile 148

Monoclonal Antibody to Target EGFR and to Inhibit PD-L1 for Oncology - Drug Profile 149

Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile 150

Recombinant Proteins to Inhibit PD-L1 for Solid Tumor - Drug Profile 151

Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile 152

SNPDL-01 - Drug Profile 153

STIA-1011 - Drug Profile 154

STIA-1012 - Drug Profile 155

STIA-1014 - Drug Profile 156

STIA-1015 - Drug Profile 157

Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile 158

Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 159

Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 160

Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 161

WBP-3155 - Drug Profile 162

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Dormant Projects 163

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Discontinued Products 164

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Featured News & Press Releases 165

Appendix 181

Methodology 181

Coverage 181

Secondary Research 181

Primary Research 181

Expert Panel Validation 181

Contact Us 181

Disclaimer 182

List of Tables

List of Tables

Number of Products under Development for, H2 2016 14

Number of Products under Development by Therapy Area, H2 2016 15

Number of Products under Development by Indication, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Development by Companies, H2 2016 (Contd..3) 26

Products under Development by Companies, H2 2016 (Contd..4) 27

Products under Development by Companies, H2 2016 (Contd..5) 28

Products under Development by Companies, H2 2016 (Contd..6) 29

Products under Development by Companies, H2 2016 (Contd..7) 30

Products under Development by Companies, H2 2016 (Contd..8) 31

Products under Development by Companies, H2 2016 (Contd..9) 32

Products under Development by Companies, H2 2016 (Contd..10) 33

Number of Products under Investigation by Universities/Institutes, H2 2016 34

Products under Investigation by Universities/Institutes, H2 2016 35

Assessment by Monotherapy/Combination Products, H2 2016 36

Number of Products by Stage and Mechanism of Action, H2 2016 37

Number of Products by Stage and Route of Administration, H2 2016 39

Number of Products by Stage and Molecule Type, H2 2016 41

Pipeline by Abeome Corporation, H2 2016 42

Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 43

Pipeline by AlphaMab Co., Ltd, H2 2016 44

Pipeline by AstraZeneca Plc, H2 2016 45

Pipeline by Aurigene Discovery Technologies Limited, H2 2016 46

Pipeline by Avacta Group Plc, H2 2016 47

Pipeline by BeiGene, Ltd., H2 2016 48

Pipeline by Bristol-Myers Squibb Company, H2 2016 49

Pipeline by CBT Pharmaceuticals Inc, H2 2016 50

Pipeline by CytomX Therapeutics, Inc., H2 2016 51

Pipeline by Eli Lilly and Company, H2 2016 52

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53

Pipeline by Genosco, H2 2016 55

Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016 56

Pipeline by Immunocore Limited, H2 2016 57

Pipeline by IO Biotech ApS, H2 2016 58

Pipeline by Kadmon Corporation, LLC, H2 2016 59

Pipeline by Kymab Limited, H2 2016 60

Pipeline by MedImmune, LLC, H2 2016 61

Pipeline by Merck KGaA, H2 2016 63

Pipeline by Merus NV, H2 2016 64

Pipeline by Novartis AG, H2 2016 65

Pipeline by PsiOxus Therapeutics Limited, H2 2016 66

Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 67

Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 68

Pipeline by Sorrento Therapeutics, Inc., H2 2016 69

Pipeline by Sutro Biopharma, Inc., H2 2016 70

Pipeline by Theravectys SA, H2 2016 71

Pipeline by Tikcro Technologies, Ltd., H2 2016 72

Dormant Projects, H2 2016 167

Discontinued Products, H2 2016 168

List of Figures

List of Figures

Number of Products under Development for, H2 2016 14

Number of Products under Development by Therapy Area, H2 2016 15

Number of Products under Development by Top 10 Indication, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Assessment by Monotherapy/Combination Products, H2 2016 36

Number of Products by Stage and Mechanism of Actions, H2 2016 37

Number of Products by Routes of Administration, H2 2016 38

Number of Products by Stage and Routes of Administration, H2 2016 38

Number of Products by Molecule Types, H2 2016 40

Number of Products by Stage and Molecule Type, H2 2016 40

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports